PERI-EDU University Education
Dyslipidaemia can alter inflammatory, vascular and skeletal biology, but most direct evidence for impaired osseointegration comes from experimental research. A lipid result contributes to the medical context and does not independently diagnose implant risk or determine eligibility.
The lipid profile in clinical context
A standard lipid profile estimates circulating cholesterol and triglyceride transport. Its main validated use is cardiovascular risk assessment and treatment. Dental clinicians may encounter these results during medical history review, but interpretation should remain aligned with the patient’s cardiovascular risk category and medical plan.
| Measure | Biological meaning | Boundary in implant care |
|---|---|---|
| Total cholesterol | Cholesterol carried across several lipoprotein classes. | A summary value that can conceal different atherogenic patterns. |
| LDL-C | Cholesterol carried in low-density lipoproteins and a central cardiovascular treatment target. | The target varies with global cardiovascular risk; no implant-specific target exists. |
| HDL-C | Cholesterol within particles involved in reverse cholesterol transport and other functions. | A high value does not neutralize elevated LDL-C or other risk. |
| Triglycerides | Lipids transported mainly in triglyceride-rich particles; elevation often accompanies insulin resistance. | Interpret with metabolic context, fasting status when relevant and secondary causes. |
| Non-HDL-C and apoB | Alternative estimates of atherogenic particle burden. | Useful in cardiovascular care but not validated as implant eligibility measures. |
LDL-C goals depend on established cardiovascular disease, diabetes, kidney disease and calculated cardiovascular risk. No cholesterol, LDL-C, HDL-C or triglyceride value has been validated as a universal threshold for implant surgery.
Dyslipidaemia and skeletal biology
Bone responds to endocrine, vascular, immune and nutritional signals. Dyslipidaemia often coexists with obesity, diabetes, metabolic liver disease, smoking and reduced physical activity. These overlapping conditions make it difficult to isolate a lipid effect in human implant studies.
- Oxidative balance: lipid oxidation can generate reactive products and amplify cellular stress.
- Inflammatory signalling: modified lipoproteins may activate endothelial, immune and stromal pathways.
- Vascular function: atherogenic particles can impair endothelial biology, although a plasma value does not measure perfusion at an implant site.
- Osteoblast-lineage cells: experimental exposure may reduce differentiation, matrix production or mineralization.
- Osteoclast pathways: oxidized lipids can modify RANKL signalling, differentiation and resorption.
Oxidized LDL and LOX-1
Oxidized LDL is a heterogeneous group of LDL particles modified by oxidative processes. It differs from the LDL-C concentration reported in a routine lipid profile. Cells can recognize modified particles through scavenger receptors, including lectin-like oxidized LDL receptor-1, known as LOX-1.
| Step | Biological event | Interpretive caution |
|---|---|---|
| Particle modification | Lipids and apolipoprotein components undergo oxidative change. | There is no single uniform oxLDL molecule or universally standardized assay. |
| Receptor recognition | LOX-1 and other scavenger receptors bind modified particles. | Expression varies by cell type and inflammatory environment. |
| Intracellular signalling | MAPK, NF-kappaB, oxidative and cytokine pathways may change. | Pathway activation in vitro does not quantify clinical implant risk. |
| Bone effects | Osteogenic differentiation, RANKL signalling and matrix turnover may be altered. | Direction and magnitude differ across experimental systems. |
Routine oxLDL or LOX-1 testing is not established for implant planning. These measurements currently belong mainly to mechanistic and translational research.
Osteoblasts, progenitor cells and marrow adiposity
Experimental lipid excess and oxidized lipids can impair osteogenic differentiation through oxidative, inflammatory and mitochondrial pathways. Progenitor activity may shift away from osteogenesis and toward adipogenic programmes. Osteoblast matrix production, mineralization and survival may also become less efficient.
Trabecular pattern and marrow density on CBCT can prompt broader clinical thinking, but CBCT cannot diagnose marrow adiposity, dyslipidaemia or oxidative stress. Imaging findings require radiological interpretation and correlation with the medical history.
Osteoclast responses are context-dependent
Lipid-related inflammation can promote osteoclastogenic signalling, yet direct oxLDL exposure has also inhibited osteoclast differentiation or resorption in experimental models. The result depends on the cell population, dose, oxidation state and surrounding cytokine environment.
A reduction in osteoclast activity is not automatically beneficial. Osseointegration requires removal of damaged bone followed by coupled formation. Excessive resorption and suppressed remodelling can both impair interface maturation.
Evidence for implant outcomes
Cell and animal studies support biological plausibility. A high-fat diet increased implant loss and reduced bone-interface formation and strength in a mouse model. Human evidence remains limited, heterogeneous and vulnerable to confounding from diabetes, obesity, smoking, periodontitis and plaque.
| Evidence layer | Contribution | Main limitation |
|---|---|---|
| Cell studies | Identify oxidative, inflammatory and bone-cell pathways. | Artificial exposure conditions and uncertain clinical dose equivalence. |
| Animal studies | Examine interface formation and mechanical strength. | Dietary models combine several metabolic changes. |
| Human observational studies | Explore lipid values, peri-implant parameters and failures. | Small samples, variable definitions and incomplete confounder adjustment. |
| Systematic reviews | Identify a possible association with complications. | Conclusions remain limited by the included evidence. |
Current evidence does not establish a validated lipid threshold for cancelling implant placement, a benefit of screening every candidate, or improvement in osseointegration after changing lipid therapy specifically for dental purposes.
Clinical assessment
- Known dyslipidaemia: record the recent profile, treatment and cardiovascular risk context when relevant.
- Metabolic comorbidity: confirm medical follow-up in patients with diabetes, obesity, hypertension or metabolic liver disease.
- Unexpected severe abnormality: advise timely medical review and coordinate elective invasive care according to overall stability.
- Repeated implant or graft complications: reassess local, mechanical, behavioural and systemic factors in parallel.
- No known metabolic risk: follow routine medical history and local assessment rather than ordering oxLDL tests solely for implant eligibility.
The triglyceride-to-HDL-C ratio can correlate with insulin resistance in some populations, but cutoffs vary. It does not replace validated diabetes testing or cardiovascular assessment and has no established implant-specific threshold.
Statins and implant care
Statins reduce atherosclerotic cardiovascular risk and remain first-line LDL-lowering therapy in appropriate patients. Their effects on bone cells and implant integration are scientifically interesting, but human implant evidence does not justify prescribing, stopping or changing a statin for dental purposes.
- Record existing lipid-lowering therapy and its medical indication.
- Do not promise improved osseointegration from systemic statin use.
- Do not use local statin delivery as a routine osseointegration protocol.
- Refer suspected intolerance or adverse effects to the prescribing clinician.
- Do not recommend supplements as substitutes for evidence-based lipid management.
Clinical synthesis
- Interpret lipid measurements within cardiovascular care rather than through an implant-specific cutoff.
- Distinguish LDL-C from oxidized LDL research assays.
- Treat oxLDL and LOX-1 as mechanistic concepts rather than routine dental biomarkers.
- Recognize context-dependent effects on osteoblast and osteoclast pathways.
- Use animal evidence to explain plausibility while acknowledging limited human translation.
- Assess local and mechanical causes whenever osseointegration or marginal bone is compromised.
- Do not modify lipid-lowering therapy for a dental hypothesis.
Download the full educational material
The full PDF presents lipid-profile interpretation, oxLDL and LOX-1 biology, osteoblast and osteoclast responses, evidence limitations, clinical assessment and medication considerations.
Download the full educational material (PDF)
Selected references
- European Society of Cardiology and European Atherosclerosis Society. 2025 focused update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.
- Sun H, et al. Effects of hyperlipidemia on osseointegration of dental implants and its strategies. 2023. PMID: 37103284.
- Gurgel BCV, et al. Are dyslipidemias a risk factor for peri-implant complications? A systematic review. 2025. PMID: 40375843.
- Keuroghlian A, et al. The effects of hyperlipidemia on implant osseointegration in the mouse femur. PMID: 24295508.
- Maziere C, et al. Oxidized LDL inhibits phosphate signalling and impairs osteoblast differentiation. PMID: 20667472.
- Dawodu D, et al. oxLDL inhibits differentiation and functional activity of osteoclasts. Scientific Reports. 2018.
- Sendyk DI, et al. The influence of statins on osseointegration: a systematic review. 2016. PMID: 27611923.
Explore related PERI-EDU resources
#UniversityEducation #OnlineCourses #ClinicalCases #PERIEDU #Dyslipidaemia #OxidizedLDL #RedoxBiology #Osseointegration
This educational material does not replace cardiovascular risk assessment, laboratory interpretation, lipid treatment or individualized implant planning.
This work was co-funded by the European Union under grant agreement No. 2024-1-PL01-KA220-HED-000251208. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the Foundation for the Development of the Education System (FRSE). Neither the European Union nor FRSE can be held responsible for them.